Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Abortion Providers Concerned About Access To Services In Wake Of Tiller Death
Abortion providers are expressing concern about future violence and access to abortion services later in pregnancy after the shooting death on Sunday of Kansas abortion provider George Tiller, the AP/San Diego Union-Tribune reports. Tiller was one of a handful of abortion providers in the U.S. who performed abortions in the third trimester of pregnancy. Tiller"s family members said they are unsure if they will reopen the clinic, which was closed after the murder (AP/San Diego Union-Tribune, 6/3). Dan Monnat, the attorney representing Tiller"s family, said that the family"s "hope is that the valuable work of Dr. Tiller will be able to continue," and that their "focus ... is to determine what is in the best interests of the employees and the patients" (Riccardi, Chicago Tribune, 6/3).Physician LeRoy Carhart said that he would like to continue to provide women with third-trimester abortion services at Tiller"s clinic, where he regularly traveled for a few days every three weeks to see patients. Carhart said that Tiller"s clinic was the only location where he performed abortions in the third trimester, and it is unclear whether he will be able to continue to offer the procedure because of the clinic"s closing. Carhart added that the continued availability of third-trimester abortion is uncertain, as many physicians in the younger generation of abortion providers are hesitant to take up the cause. Few schools and universities offer programs to train physicians to perform the procedure, and those who might be interested are concerned about violence, Carhart said (AP/San Diego Union-Tribune, 6/3). According to NPR"s "All Things Considered," U.S. marshals have been sent to protect abortion clinics and providers throughout the country in the wake of Tiller"s murder.Some abortion-rights supporters called on officials to do more to draw attention to the effects of violence on access to abortion services. Abortion provider Warren Hern, a friend of Tiller"s who also performs the procedure during the third trimester, said that President Obama needs to do more than condemn Tiller"s murder and violence against abortion providers. He said that Obama "needs to go on a national television broadcast and say to the American public, "Safe abortion is a fundamental component of women"s health care. Antiabortion terrorism and violence will not be tolerated. We will stop you."" Nancy Northup, president of the Center for Reproductive Rights, said, "We need to hear from our officeholders, from doctors, from religious leaders, from the community." She added, "(W)e can"t stop the voices of those who will continue to vilify and demonize, but what we can do is we need to have more voices standing up for these doctors" (Lohr, "All Things Considered," NPR, 6/2).Suspect Charged Kansas prosecutors on Tuesday formally charged Scott Roeder with murder for allegedly killing Tiller, the Chicago Tribune reports. The charge carries a maximum sentence of life in prison because the crime does not fit the state"s legal requirements for the death penalty, Sedgwick County District Attorney Nola Foulston said. The charges against Roeder also include two counts of aggravated assault for wielding his firearm at two individuals who tried to stop him (Chicago Tribune, 6/3).
generic viagra online
Sorin Group Announces Regulatory Approval And First Implants Of New-Platform FACIL And REPLY Pacemakers In Japan
Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced the Ministry of Health, Labor and Welfare (MHLW) approval to market the FACIL™ and REPLY™ families of dual and single chamber rate responsive pacemakers.
News of the day
Extreme Sports Not About Risk-taking: Study
Those who think extreme sports are all about risk-taking are missing the point, according to a QUT researcher. Eric Brymer, a lecturer from the School of Human Movement Studies in the Faculty of Health, has been researching whether the element of risk was an important factor among participants in "extreme" sports such as waterfall kayakers, mountain climbers, big wave surfers and B.A.S.E. jumpers.
Medical Devices

White House: Shield Biotech Drugs From Generics For Only Seven Years

White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports. "The amount of protection for brand-name companies is a sticking point among lawmakers working to set up a legal pathway for approval of generic forms of biotech drugs. The brand-name versions can cost tens of thousands of dollars per year. Industry groups representing brand-name makers are lobbying for 12 to 14 years, saying it is crucial for encouraging companies to invest in development of new medicines." The White House, "in a letter to Rep. Henry Waxman, D-Calif., said "seven years strikes the appropriate balance between innovation and competition by providing for seven years of exclusivity."" The biologic drugs are man-made versions of human proteins and treat conditions like anemia, rheumatoid arthritis and cancer, Reuters reports. The drug industry is worried that such a move will make researching and developing new drugs less attractive to drug makers (Richwine, 6/25). Bloomberg: "Unlike conventional pills, biologics can"t be copied even after patents expire. Patient groups, payers and generic drugmakers have battled biotechnology companies for more than two years over how to allow competition. ò€¦ Amgen, of Thousand Oaks, California, and Genentech, a unit of Swiss drugmaker Roche, are the largest U.S. makers of biologics. They say their medicines can"t be replicated like conventional pills produced through chemical synthesis because of complex manufacturing and finished products that have slight variances ... Generic biologics may be sold at a 10 percent to 30 percent discount, allowing for "substantial consumer savings" without eroding market share for brand-name drug companies, the Federal Trade Commission said in a June 10 report" (Larkin, 6/25). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009